MEETING THE CHALLENGE OF ATOPIC DERMATITIS FROM INFANCY TO ADULTHOOD

Mar
2017
Vol. 36. No. 2

Introduction

Atopic dermatitis (AD) has a significant, lifelong clinical impact on affected individuals and has profound effects on quality of life both for patients and their families.

If you would like to complete the CME portion of this Supplement, please click here.

Atopic Dermatitis Progression: Evaluating Intervention Strategies

Lawrence F. Eichenfield, MD | Linda Stein Gold, MD

Several risk factors have been identified that appear to be consistently and strongly associated with the development of atopic dermatitis (AD): a family history of atopy, an inherited genetic predisposition, and active and passive exposure to tobacco smoke.

If you would like to complete the CME portion of this Supplement, please click here.

MORE

Nonpharmacologic Strategies and Topical Agents for Treating Atopic Dermatitis: An Update

Lawrence F. Eichenfield, MD | Linda Stein Gold, MD

The signs and symptoms of atopic dermatitis can be safely and effectively controlled in most patients; in many cases, the disease can be improved to the point that signs and symptoms are absent or minimal. In addition, flares can be effectively controlled and, in some cases, prevented.

If you would like to complete the CME portion of this Supplement, please click here.

MORE

Addressing the Immunopathogenesis of Atopic Dermatitis: Advances in Topical and Systemic Treatment

Lawrence F. Eichenfield, MD | Linda Stein Gold, MD

Several immunologic mediators—phosphodiesterase (PDE), interleukin (IL), small molecules, and Janus kinase—have been implicated in the pathogenesis of atopic dermatitis, and evidence has shown that blocking these mediators can help modify the disease process.

Eichenfield LF, Stein Gold LF. Addressing the immunopathogenesis of atopic dermatitis: advances in topical and systemic treatment. Sem Cutan Med Surg. 2017;36(Suppl 2):S45-S48. https://doi.org/10.12788/j.sder.2017.012.

If you would like to complete the CME portion of this Supplement, please click here.

MORE